Abstract

BackgroundIn Ethiopia, MDR-TB has become a significant public health threat; therefore, the Ministry of Health introduced two treatment approaches for MDR-TB cases: treatment initiative center (TIC) and treatment follow-up center (TFC). TIC is where patients usually are diagnosed and start the treatment. At TFC, we follow MDR-TB patients until they completed the treatment. However, there is no evidence about the cost-effectiveness of the approaches. Therefore, this study aimed to analyze the cost-effectiveness of MDR-TB treatment in TIC and TFC.MethodsIn this study, we employed a full economic evaluation from a providers' perspective. We followed a hypothetical cohort of individuals from the age of 15 for a lifetime using a Markov model with five mutually exclusive health states. We used both primary and secondary data sources for the study. Ingredient-based costing approach was used. The costs include healthcare provider costs (recurrent and capital cost) and patient-side costs (direct and indirect). We use a human capital approach to estimate the indirect cost. The cost estimates were reported in the 2017 United States Dollar (US$), and effectiveness was measured using disability-adjusted life-years (DALYs) averted. Both costs and health benefits were discounted using a 3% discount rate. Both average and incremental cost-effectiveness ratios (ICER) were reported calculated. One-way and probabilistic sensitivity analyses were reported to determine the robustness of the estimates.ResultsThe cost per HIV negative patient successfully treated for MDR-TB was $8,416 at TIC and $6,657 at TFC. The average cost-effectiveness ratio per DALY averted at TFC was $671 and $1,417 per DALY averted at TIC. The incremental cost-effectiveness ratio (ICER) of MDR-TB treatment at TIC was $1,641 per DALYs averted.ConclusionThis study indicates that the treatment of MDR-TB at both TIC and TFC are cost-effective interventions compared with the willingness to pay threshold of three-times the GDP per capita in Ethiopia.

Highlights

  • Multidrug-resistance Tuberculosis (MDR-TB) remains to be a considerable challenge globally and in Ethiopia

  • The cost per HIV negative patient successfully treated for MDR-TB was $8,416 at Treatment Initiation Centers (TIC) and $6,657 at Treatment Follow-up Centers (TFC)

  • The average cost-effectiveness ratio per disability-adjusted life-years (DALYs) averted at TFC was $671

Read more

Summary

Introduction

Multidrug-resistance Tuberculosis (MDR-TB) remains to be a considerable challenge globally and in Ethiopia. Treatment of patients with MDR-TB is more complicated than drug-susceptible cases because of reasons related to adherence, adverse effect of the drugs, and cost. The Ethiopian Federal Ministry of Health (FMoH) developed a national MDR-TB treatment guideline, slightly modifying the recommendations outlined in the WHO guideline. This guide recommends two distinct approaches/level for MDR-TB treatment. The first is Treatment Initiation Centers (TIC), where patients usually are diagnosed and start the therapy. In Ethiopia, MDR-TB has become a significant public health threat; the Ministry of Health introduced two treatment approaches for MDR-TB cases: treatment initiative center (TIC) and treatment follow-up center (TFC). TIC is where patients usually are diagnosed and start the treatment. At TFC, we follow MDR-TB patients until they completed the treatment. This study aimed to analyze the cost-effectiveness of MDR-TB treatment in TIC and TFC

Objectives
Methods
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call